Latest Videos

Brachytherapy: What’s New and Where are We Going?

Peter J. Rossi, MD, a board-certified radiation oncologist affiliated with Calaway Young Cancer Center at Valley View Hospital in Glenwood Springs, Colorado discusses innovations and advances in low-dose-rate (LDR) and high-dose-rate (HDR) prostate brachytherapy as well as American Brachytherapy Society (ABS) initiatives and training opportunities. Dr. Rossi explains that innovations have resulted in brachytherapy treatment that is evidence-based, innovative, efficient, cost effective, flexible, yields highly personalized treatment, and is of high value to multidisciplinary teams and to patients.

Read More

Personalization of Prostate Cancer Care Through Integration of Data

In this presentation, given during the 2021 Virtual Global Summit on Precision Diagnosis and Treatment of Prostate Cancer and supported by Philips, Ilya Gipp, MD, PhD, a medical officer and oncology solutions subject matter expert with Philips in Atlanta, Georgia, discusses solutions for integrating data to personalize prostate cancer care. He first describes positive trends and challenges in prostate cancer care, noting that data silos across service lines and service providers remain a key barrier to effective and efficient treatment. Dr. Gipp describes the prostate cancer service line as beginning with early detection, progressing to diagnosis and staging, treatment selection, therapy planning and deployment, and assessment and follow-up. He then focuses on the actionability and insightfulness of information, and how to synthesize data throughout the cancer care pathway using magnetic resonance imaging (MRI). Dr. Gipp remarks that while MRI is often used in diagnosis, to benefit from the data, MRI must be the modality used at all points from screening to post-therapy assessment. For example, MRI can generate images similar to CT scans for radiation dose planning as well as guiding dose painting to offer localized, non-uniform radiation dose distribution. He summarizes by comparing the traditional approach to cancer care with a state-of-the-art model that employs biomarker imaging, image-guided multi-modality navigated fusion biopsies, digital pathology, and focal therapies.

Read More

Experience with 18F-rhPSMA7.3 for Prostate Cancer

In this 6-minute presentation, presented during the 2021 Virtual Global Summit on Precision Diagnosis and Treatment of Prostate Cancer and supported by Blue Earth Diagnostics, Wolfgang Weber, MD, Professor and Chair of the Department of Nuclear Medicine at the Technical University of Munich in Germany (TUM), discusses 18F-rhPSMA7(.3) as a promising tracer for imaging prostate cancer for primary staging and in the case of biochemical recurrence, explaining that limited renal excretion facilitates evaluation of the prostate and the prostate bed before surgery. Dr. Weber explains that prospective registration trials have completed accrual, and the use of radiohybrid prostate-specific membrane antigen ligands (rhPSMAs) for therapy of prostate cancer is being evaluated preclinically.

Read More

Join the GRU Community

- Why Join? -